A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

An Open-label Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05539976

Enrollment

Registered

2022-09-14

Start date

2022-09-30

Completion date

2022-11-14

Last updated

2022-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Participants

Brief summary

The purpose of this study is to develop taste profiles of iberdomide and mezigdomide drug substances and oral formulation prototypes in order to develop a pediatric oral form of iberdomide and mezigdomide.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Participant is qualified based on training and experience. * Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling. * Participant is qualified based on training and experience. * Senopsys LLC will provide all participants. * Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling.

Exclusion criteria

* Participant has any history of any illness, medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the investigator, might confound the results of the study or places the participant at unacceptable risk if he or she were to participate in the study. * Participant has a known hypersensitivity to mezigdomide, iberdomide, thalidomide, lenalidomide, or pomalidomide. * Participant is a female that is pregnant, breastfeeding, or is a women of childbearing potential (WOCBP).

Design outcomes

Primary

Measure	Time frame
Taste Evaluation - Aromatic Identity	Up to 3 Months
Taste Evaluation - Amplitude	Up to 3 Months
Taste Evaluation - Mouthfeel	Up to 3 Months
Taste Evaluation - Off-notes	Up to 3 Months
Taste Evaluation - Aftertaste	Up to 3 Months

Countries

United States

Outcome results